Literature DB >> 25358830

Moderately increased albuminuria unmasked hypertension.

Salvador Pertusa1, Carlos Ramos-Lopez1, Martha Martinez-Navas1, Ana Palacios-Marqués2.   

Abstract

The normal rate of albumin excretion is less than 30 mg/day (20 µg/min); persistent albumin excretion between 30 and 300 mg/day (20-200 µg/min) is called moderately increased albuminuria (formerly called microalbuminuria). In addition to being associated with diabetic nephropathy, moderately increased albuminuria has also been associated with cardiovascular disease in patients with as well as without diabetes. We present a case report of a man with moderately increased albuminuria who developed hypertension only detected by an ambulatory blood pressure monitoring procedure. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25358830      PMCID: PMC4216896          DOI: 10.1136/bcr-2013-202643

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension.

Authors:  Ramón C Hermida; Diana E Ayala; Carlos Calvo; José E López; Artemio Mojón; María J Fontao; Rita Soler; José R Fernández
Journal:  Hypertension       Date:  2005-08-08       Impact factor: 10.190

2.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

3.  Atherosclerosis profile and microalbuminuria in essential hypertension.

Authors:  J Calviño; C Calvo; R Romero; F Gude; D Sánchez-Guisande
Journal:  Am J Kidney Dis       Date:  1999-12       Impact factor: 8.860

Review 4.  Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.

Authors:  C E Mogensen; E Vestbo; P L Poulsen; C Christiansen; E M Damsgaard; H Eiskjaer; A Frøland; K W Hansen; S Nielsen; M M Pedersen
Journal:  Diabetes Care       Date:  1995-04       Impact factor: 19.112

5.  Low-grade albuminuria and the risks of hypertension and blood pressure progression.

Authors:  Thomas J Wang; Jane C Evans; James B Meigs; Nader Rifai; Caroline S Fox; Ralph B D'Agostino; Daniel Levy; Ramachandran S Vasan
Journal:  Circulation       Date:  2005-02-28       Impact factor: 29.690

6.  Chronotherapy: a smart approach for refractory hypertension.

Authors:  Salvador Pertusa; Domingo Orozco-Beltran
Journal:  BMJ Case Rep       Date:  2009-07-26

7.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

8.  Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.

Authors:  Kristian Wachtell; Michael H Olsen; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Markku S Nieminen; Peter M Okin; Vasilios Papademetriou; Carl E Mogensen; Knut Borch-Johnsen; Hans Ibsen
Journal:  J Hypertens       Date:  2002-03       Impact factor: 4.844

9.  Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.

Authors:  Hans Ibsen; Kristian Wachtell; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Journal:  J Hypertens       Date:  2004-09       Impact factor: 4.844

10.  Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension.

Authors:  Ramón C Hermida; Diana E Ayala; José R Fernández; Carlos Calvo
Journal:  Hypertension       Date:  2007-10-29       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.